Related Experiment Video
Updated: Jun 19, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Implementation of spacer therapy for acute asthma in children
1Department of Paediatrics, Cork University Hospital, Wilton, Cork.
Insights
Implementing evidence-based guidelines for acute asthma treatment improved patient care. The new approach led to shorter hospital stays and more effective use of metered dose inhalers with spacers.
Area of Science:
- Pediatrics
- Respiratory Medicine
- Evidence-Based Medicine
Background:
- Acute asthma management in children requires standardized, evidence-based protocols.
- Metered dose inhalers (MDIs) with spacers are effective delivery devices for pediatric asthma treatment.
Purpose of the Study:
- To develop and implement an evidence-based guideline for acute asthma treatment in pediatric patients.
- To evaluate the impact of the new guideline on patient management and outcomes.
Main Methods:
- A pre- and post-intervention audit of pediatric asthma admissions was conducted.
- Case notes were reviewed to assess compliance with guidelines focusing on patient assessment, spacer use, and discharge criteria.
Main Results:
- Guideline implementation resulted in a higher threshold for admission for mild exacerbations.
- Post-implementation, there was a reduced duration of admission and bronchodilator therapy, with earlier initiation of oral corticosteroids.
- Spacer device use for bronchodilator delivery increased significantly, alongside improved documentation of asthma education and action plans.
Conclusions:
- Evidence-based guidelines improve the management of acute pediatric asthma.
- The use of metered dose inhalers with spacers should be emphasized for efficient bronchodilator delivery.
- Standardized protocols enhance patient assessment, treatment, and education, leading to better outcomes.
Abstract:
The aim was to develop and implement an evidence based guideline for the treatment of acute asthma using a metered dose inhaler and spacer combination. Children admitted to Cork University Hospital Paediatric Department with acute asthma were identified during two identical 2 month seasonal periods before (2005) and after (2006) implementation of the new guidelines in September 2006. Pre-intervention and post-intervention audits by case note review were performed to determine the impact of and compliance with this evidence-based guideline emphasising patient assessment, spacer delivered bronchodilator and specific discharge criteria. Patients had similar characteristics during the two study periods. There was a raised threshold for admission after guideline implementation with 11/52 patients having mild exacerbations in 2006, compared to 21/36 in 2005. Duration of admission was less in the post-implementation group for equivalent exacerbation severity e.g. for moderate severity; 28 hours in 2005, 23 hours in 2006. Duration of bronchodilator therapy was shorter in 2006 and more likely to be given by spacer device earlier for equivalent levels of severity e.g. for moderate exacerbations, in 2006 the average length of salbutamol therapy was 18 hours with 12 hours by spacer device, in 2005 the average length of therapy was 25 hours with 3 hours by spacer. There was earlier initiation of oral corticosteroids; the average time to administration was 56 minutes in 2006 and 227 minutes in 2005. There was an improved documentation of asthma education in 2006 e.g. inhaler technique was reviewed in 37/52 in 2006, 21/35 in 2005 and better use of written action plans.
Related Concept Videos
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Inhaled Medications
Asthma-IV: Nursing Management
First, in...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...